Selected article for: "immune system and patient recovery"

Author: Saburi, Ehsan; Abazari, Mohamadfoad; Hasannia, Hadi; Nassiri mansour, Reyhaneh; Eshaghi-Gorji, Reza; Gheibi, Mobina; Rahmati, Mohamad; Ehsan Enderami, Seyed
Title: The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19
  • Cord-id: qh5s5fd8
  • Document date: 2021_2_4
  • ID: qh5s5fd8
    Snippet: In addition to causing health concerns, the new coronavirus has been considered in the world with its unknown mechanism of physiopathogenesis and long-term effects after patient recovery. Pulmonary, renal, hepatic and cardiac complications have been reported so far. Beside the researchers' focus on finding vaccines and using conventional therapies, cell-based therapy might be an effective therapeutic strategy. The use of mesenchymal stem cells (MSCs) is one of the options due to their immunomodu
    Document: In addition to causing health concerns, the new coronavirus has been considered in the world with its unknown mechanism of physiopathogenesis and long-term effects after patient recovery. Pulmonary, renal, hepatic and cardiac complications have been reported so far. Beside the researchers' focus on finding vaccines and using conventional therapies, cell-based therapy might be an effective therapeutic strategy. The use of mesenchymal stem cells (MSCs) is one of the options due to their immunomodulatory properties and their proven effects in the treatment of many diseases. As MSCs are not infected with covid-19, there is evidence that it modulates the immune system and prevents the virus from clotting. Despite the beginning of numerous clinical trials in the use of mesenchymal stem cells, it is necessary to set a practical guideline that specifies items such as cell origin, number of cells, frequency of injection, injection site, etc.

    Search related documents:
    Co phrase search for related documents
    • abundant evidence and acute phase: 1
    • acute heart and adipose tissue: 1, 2, 3
    • acute illness and adipose tissue: 1
    • acute phase and adipose tissue: 1
    • acute phase and low efficacy: 1, 2
    • acute phase protein and adipose tissue: 1
    • acute phase protein and low efficacy: 1
    • additional aspect and low efficacy: 1